<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505164</url>
  </required_header>
  <id_info>
    <org_study_id>16022426</org_study_id>
    <nct_id>NCT03505164</nct_id>
  </id_info>
  <brief_title>The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor</brief_title>
  <official_title>The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks to find a causative or predictive aspect of the suPAR biomarker for heart
      failure in breast cancer patients receiving Doxorubicin drug chemo regimen.

      suPAR is a circulating protein which can be found in blood and/or urine and is associated
      with both kidney and heart disease.

        -  Hypothesis 1: Higher suPAR at baseline will predispose to Doxorubicin-induced
           cardiomyopathy or heart failure, observed by histology (under the microscope and other
           lab techniques) in mouse models, and tested using heart ultrasound techniques in humans.

        -  Hypothesis 2: suPAR is a marker of Doxorubicin-induced cardiomyopathy or heart failure
           after exposure to Doxorubicin, observed by histology (under the microscope and other lab
           techniques) in mouse models, and tested in humans.

      The study will look at suPAR's association with three other biomarkers called troponin,
      B-Type Natriuretic Peptide (BNP) and C- Reactive Protein (CRP) that are also associated with
      heart disease.

      In this study, the patient will have blood drawn as a routine part of the cancer treatment.
      That is prior to starting the cancer therapy, then after the first 2 and last 2 doxorubicin
      cycles (4 cycles altogether); as well as at 3, 6, &amp; 12 months after doxorubicin treatment. (6
      Visits in total) The patient will also have an echocardiogram (echo, heart ultrasound) at
      each of these time points. The first of the six study echos is considered part of the routine
      care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Hypothesis 1: Higher suPAR at baseline will predispose to DOX-induced cardiomyopathy to
           be observed by histology in mouse models, and tested using LVEF (Left Ventricular
           Ejection Fraction) assessment, and surrogate cardiovascular outcome measures as
           described in humans.

        -  Hypothesis 2: suPAR is a marker of DOX-induced cardiomyopathy after exposure to DOX, to
           be observed by histology in mouse models, and tested using surrogate cardiovascular
           outcome measures as described in humans.

             1. Patients meeting outlined eligibility criteria are identified by breast cancer
                physicians working in the Rush Cancer Center. After eligibility is verified,
                patients are approached by the study coordinators or research fellow to discuss
                participation in the trial while patients were being seen by their provider within
                the cancer center and given the informed consent form for review. Patients are
                contacted approximately one week later to answer questions and plan for baseline
                visit if interested in enrolling.

             2. After signing the informed consent form, patients are officially enrolled. The
                research nurse, study coordinator, or research fellow will conduct research visits
                at each of the six study time points outlined in the protocol: pre-chemo, post-2
                cycles of doxorubicin, post-4 cycles of doxorubicin, 3 months post-doxorubicin, 6
                month post-doxorubicin and 12 months post-doxorubin

             3. Each study visit consists of collecting lab work via blood draw as detailed in the
                protocol as well as an echocardiogram performed with strain.

             4. Results from each test are collected, reviewed by the PI and documented in the
                patient's study binder.

             5. Preliminary human results have not been analyzed at this time as there is currently
                insufficient data collected.

      In the laboratory approach of the study, the investigators aimed to establish the role of
      suPAR in DOX induced cardiomyopathy. The risk for DOX induced cardiomyopathy is known to
      increase with an increase of the accumulative dose. The investigators therefore used two
      doses of DOX. One group of mice received weekly injections of DOX at 3mg/kg bodyweight for 6
      week (accumulative dose of 18mg/kg: DOX18) whereas another group received an accumulative
      dose of 25mg/kg bodyweight (DOX25: 5 weeks, at 5 mg/kg bodyweight). Blood samples were taken
      before the first injection, in the middle of treatment and at the end of treatment or at the
      day of sacrifice. The bodyweight of the animals was constantly monitored throughout the
      study.

      At time of sacrifice, the heart weight and tibia length of the mice were quantified and cells
      were isolated to determine cellular levels of reactive oxygen species (ROS), contractility
      and Ca handling properties.

      DOX induced cardiomyopathy can manifest years after treatment. Tissue samples from hearts of
      the DOX18 and DOX25 treatment group were obtained and quantitative PCR (Polymerase Chain
      Reaction amplification) of the ventricular tissue will help us determine the changes in
      protein expression and cellular signaling that underlie these DOX induced changes in cellular
      function.

      Blood samples obtained from the DOX18 and DOX25 mice will be analyzed for their level of
      suPAR to determine changes in suPAR over the duration of treatment and potential correlations
      of [suPAR] with the degree of cardiac dysfunction.

      The data collected will be analyzed using a descriptive analysis with means and standard
      deviations for continuous variables and percentages for categorical variables. A paired
      t-test comparing the pre-post difference will be used to compare the differences in the
      groups comparing pre to post measures of myocardial damage based on histology for mouse
      models, and LVEF (Left Ventricular Ejection Fraction) for human data. Analysis will be
      performed using SAS Software.

      The expected results from the data collected in this study aim to both gain an understanding
      of and describe the relationship of various covariates to primary outcomes.

      It is expected to have 50 participants by the study end date. There is a trained team working
      on the study, insuring quality of data gathering, recruitment and enrollment of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Causality relationship between the suPAR blood level and doxorubicin-induced cardiomyopathy</measure>
    <time_frame>12 months</time_frame>
    <description>A blood draw will be done at baseline for all participants. The blood samples will be processed by Centrifugation, to separate the plasma, and the suPAR level measured using ELISA technique, to stratify the participants that have a higher or normal baseline.
Although there is no current consensus regarding normal suPAR blood level, a level of 3000 pg/mL is considered a high level.
Higher baseline blood level of suPAR, will predispose patients with breast cancer undergoing chemo regimen containing doxorubicin, to develop heart toxicity (heart failure or cardiomyopathy).
Heart failure or Cardiomyopathy will be diagnosed by the clinical evaluation with signs and symptoms, LVEF (Left Ventricular Ejection Fraction) with echocardiograms (heart ultrasound), and surrogate cardiovascular outcome measures as described in humans, and tissue visualization and histology in mouse models, with various staining techniques, whether it was H&amp;E staining, or other immunological staining.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive relationship between suPAR blood level and doxorubicin-induced cardiomyopathy</measure>
    <time_frame>12 months</time_frame>
    <description>A blood draw will be done at baseline for all participants. The blood samples will be processed by Centrifugation to separate the plasma, and the suPAR level measured using ELISA technique, to stratify the participants having a higher or normal baseline.
Although there is no current consensus regarding normal suPAR blood level, a level less than 3000 pg/mL is considered a normal level.
A normal baseline blood level of suPAR, with progressive elevation following doxorubicin exposure, along with other blood markers for heart failure, will be considered as a predictive marker for doxorubicin-induced cardiomyopathy.
Heart failure or Cardiomyopathy will be diagnosed by the clinical evaluation with signs and symptoms, LVEF (Left Ventricular Ejection Fraction) with echocardiograms (heart ultrasound), and surrogate cardiovascular outcome measures as described in humans, and tissue visualization and histology in mouse models using H&amp;E staining, or other immunological staining techniques.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Doxorubicin Adverse Reaction</condition>
  <condition>Cardiomyopathies, Secondary</condition>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are put in a Centrifugation machine to separate the plasma. The plasma is then
      kept in -70 to -80 degrees Fahrenheit. Each sample will be studied for suPAR levels.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients aged between 18 and 64, recently diagnosed with non metastatic breast
        cancer, and will be receiving doxorubicin containing chemo regimen.

        All patients are being treated at Rush University Medical Center, Chicago, IL, and Rush Oak
        Park Hospital, Oak Park, IL.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 64 years

          -  Undergoing chemotherapy in the Rush cancer center with a plan for doxorubicin
             (AdriamycinÂ®) chemotherapy.

        Exclusion Criteria:

          -  Patients with metastatic breast cancer - complicated chemotherapy regimens, higher
             mortality risk

          -  HER2 positive breast cancer patients planned for trastuzumab therapy

          -  Patients with baseline cardiomyopathy (reduced LVEF: less than 50%)

          -  Patients with prior cardiovascular history of myocardial infarction (MI), angina,
             Congestive Heart Disease (CHD) death, coronary artery bypass grafting (CABG),
             percutaneous coronary intervention (PCI) including percutaneous transluminal coronary
             angioplasty (PTCA) and end-stage renal disease (ESRD), atrial fibrillation prior to
             cancer diagnosis

          -  Atrial fibrillation noted on baseline ECG
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tochi Okwuosa, DO, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tochi Okwuosa, DO, FACC</last_name>
    <phone>312-942-4601</phone>
    <phone_ext>9610</phone_ext>
    <email>tokwuosa@rush.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tochi Okwuosa, DO, FACC</last_name>
      <phone>312-942-4601</phone>
      <phone_ext>9610</phone_ext>
      <email>tokwuosa@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Tochi Okwuosa, DO, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Banach, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changli Wei, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Oak Park Hospital</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tochi Okwuosa, DO, FACC</last_name>
      <phone>312-942-4601</phone>
      <phone_ext>9610</phone_ext>
      <email>tokwuosa@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Tochi Okwuosa, DO, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Banach, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changli Wei, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Tochukwu Okwuosa</investigator_full_name>
    <investigator_title>Tochukwu M. Okwuosa, DO, FACC, Assistant Professor of Medicine and Cardiology, Director of Cardio-Onc Services, Principal Investigator in the suPAR pilot study.</investigator_title>
  </responsible_party>
  <keyword>Doxorubicin</keyword>
  <keyword>suPAR</keyword>
  <keyword>Caridomyopathy</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

